Lexicon Pharmaceuticals Inc logo

LXRX - Lexicon Pharmaceuticals Inc Share Price

$1.32 -0.0  -1.5%

Last Trade - 27/10/20

Sector
Healthcare
Size
Small Cap
Market Cap £108.4m
Enterprise Value £141.7m
Revenue £245.6m
Position in Universe 4017th / 6406
Bullish
Bearish
Unlock LXRX Revenue
Momentum
Relative Strength (%)
1m -14.4%
3m
6m
1yr
Volume Change (%)
10d / 3m
Price vs... (%)
52w High -75.2%
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 31st Dec 2014 2015 2016 2017 2018 2019 2020E 2021E CAGR / Avg
22.9 130 79.3 91.7 63.2 322.1 83.5 3.27 +69.7%
PEG
Profitability
ROA
%
%
Cashflow
Dividends
Balance Sheet
NFA
m
FINANCIAL BRIEF: : For the six months ended 30 June 2020, LexiconPharmaceuticals, Inc. revenues decreased 9% to $17.2M. Netloss increased from $44.8M to $135.7M. Revenues reflectCollaborative agreements decrease of 99% to $33K. Highernet loss reflects Research and development -other increasefrom $21M to $108.4M (expense), Stock-based Compensation inSGA increase of 30% to $4.6M (expense), Stock-basedCompensation in R&D increase of 12% to $4.1M (expense).
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Distress
Cautious
Safe
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History

Revenue

LXRX Revenue Unlock LXRX Revenue

Net Income

LXRX Net Income Unlock LXRX Revenue

Normalised EPS

LXRX Normalised EPS Unlock LXRX Revenue

PE Ratio Range

LXRX PE Ratio Range Unlock LXRX Revenue

Dividend Yield Range

LXRX Dividend Yield Range Unlock LXRX Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2020
31st Dec 2021
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2019 /  2020
LXRX EPS Forecasts Unlock LXRX Revenue
Profile Summary

Lexicon Pharmaceuticals, Inc. is a biopharmaceutical company. The Company focuses on the development and commercialization of treatments for human disease. The Company's drug programs include Sotagliflozin and LX9211. The Company also has a number of additional compounds into various stages of clinical and preclinical development. The Company’s LX9211 is an orally-delivered small molecule compound that is being developed for the treatment of neuropathic pain. The Company intends to initiate a Phase IIa clinical trial evaluating the safety and tolerability of LX9211 and its effects on diabetic peripheral neuropathic (DPN) pain. Its Sotagliflozin is an orally-delivered small molecule compound that is being developed for the treatment of type I diabetes and type II diabetes, heart failure and chronic kidney disease.

Directors
Last Annual December 31st, 2019
Last Interim June 30th, 2020
Incorporated July 7, 1995
Public Since April 7, 2000
No. of Shareholders: 359
No. of Employees: 184
Sector Healthcare
Industry Biotechnology & Medical Research
Index Nasdaq Composite ,
Exchange NASDAQ Global Select Market
Shares in Issue 107,105,853
Free Float (0.0%)
Eligible for
ISAs
SIPPs
LXRX Share Price Performance
Share Price
Bid - Ask
Low - High
Spread
Day's Change
Avg Volume
Open - Close
Range (12m)
Beta
Latest News for LXRX
Upcoming Events for LXRX
Thursday 29th October, 2020
Q3 2020 Lexicon Pharmaceuticals Inc Earnings Call
Thursday 5th November, 2020 Estimate
Q3 2020 Lexicon Pharmaceuticals Inc Earnings Release
Wednesday 10th March, 2021 Estimate
Q4 2020 Lexicon Pharmaceuticals Inc Earnings Release
Monday 26th April, 2021 Estimate
Q1 2021 Lexicon Pharmaceuticals Inc Earnings Release
Frequently Asked Questions for Lexicon Pharmaceuticals Inc
What is the Lexicon Pharmaceuticals Inc share price?

As of 27/10/20, shares in Lexicon Pharmaceuticals Inc are trading at $1.32, giving the company a market capitalisation of £108.4m. This share price information is delayed by 15 minutes.

How has the Lexicon Pharmaceuticals Inc share price performed this year?

Shares in Lexicon Pharmaceuticals Inc are currently trading at $1.32 and the price has moved by -67.16% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Lexicon Pharmaceuticals Inc price has moved by -70.68% over the past year.

What are the analyst and broker recommendations for Lexicon Pharmaceuticals Inc?

Of the analysts with advisory recommendations for Lexicon Pharmaceuticals Inc, there are there are currently 1 "buy" , 4 "hold" and 0 "sell" recommendations. The overall consensus recommendation for Lexicon Pharmaceuticals Inc is Hold. You can view the full broker recommendation list by unlocking its StockReport.

When will Lexicon Pharmaceuticals Inc next release its financial results?

Lexicon Pharmaceuticals Inc is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2021-06-30
What is the Lexicon Pharmaceuticals Inc dividend yield?

Lexicon Pharmaceuticals Inc does not currently pay a dividend.

Does Lexicon Pharmaceuticals Inc pay a dividend?

Lexicon Pharmaceuticals Inc does not currently pay a dividend.

When does Lexicon Pharmaceuticals Inc next pay dividends?

Lexicon Pharmaceuticals Inc does not currently pay a dividend.

How do I buy Lexicon Pharmaceuticals Inc shares?

To buy shares in Lexicon Pharmaceuticals Inc you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of Lexicon Pharmaceuticals Inc?

Shares in Lexicon Pharmaceuticals Inc are currently trading at $1.32, giving the company a market capitalisation of £108.4m.

Where are Lexicon Pharmaceuticals Inc shares listed? Where are Lexicon Pharmaceuticals Inc shares listed?

Here are the trading details for Lexicon Pharmaceuticals Inc:

Country of listing: United States
Exchange: NSQ
Ticker Symbol: LXRX
What kind of share is Lexicon Pharmaceuticals Inc?

Based on an overall assessment of its quality, value and momentum, Lexicon Pharmaceuticals Inc is currently classified as a Value Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.

Is there a Lexicon Pharmaceuticals Inc share price forecast 2020?

Shares in Lexicon Pharmaceuticals Inc are currently priced at $1.32. At that level they are trading at 0.105% discount to the analyst consensus target price of 0.00.

Analysts covering Lexicon Pharmaceuticals Inc currently have a consensus Earnings Per Share (EPS) forecast of -1.209 for the next financial year.

How can I tell whether the Lexicon Pharmaceuticals Inc share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Lexicon Pharmaceuticals Inc. Over the past six months, the relative strength of its shares against the market has been -41.87%. At the current price of $1.32, shares in Lexicon Pharmaceuticals Inc are trading at -36.66% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the Lexicon Pharmaceuticals Inc PE Ratio?

The Lexicon Pharmaceuticals Inc PE ratio based on its reported earnings over the past 12 months is 3.65. The shares are currently trading at $1.32.

The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.

The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.

Who are the key directors of Lexicon Pharmaceuticals Inc?

Lexicon Pharmaceuticals Inc's management team is headed by:

Jeffrey Wade - CFO
Samuel Barker - IND
Robert Lefkowitz - IND
Alan Main - EVP
Alan Nies - IND
Frank Palantoni - IND
Raymond Debbane - CHM
Philippe Amouyal - IND
James Tessmer - VFN
Lonnel Coats - PRE
Praveen Tyle - EVP
Brian Crum - VPR
Who are the major shareholders of Lexicon Pharmaceuticals Inc?

Here are the top five shareholders of Lexicon Pharmaceuticals Inc based on the size of their shareholding:

Artal International S.C.A. Investment Advisor
Percentage owned: 52.96% (56.7m shares)
Fidelity Management & Research Company LLC Investment Advisor
Percentage owned: 10.29% (11.0m shares)
Fidelity Growth Company Fund Mutual Fund
Percentage owned: 4.11% (4.40m shares)
Ulys, L.L.C. Investment Advisor
Percentage owned: 4.03% (4.32m shares)
BlackRock Institutional Trust Company, N.A. Investment Advisor
Percentage owned: 3.63% (3.89m shares)
Similar to LXRX
© Stockopedia 2020, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.